NMPA Announces 26 New Medical Device Industry Standards; Healthcare Innovation ETF (516820) Gains Attention Amid Strong Sector Momentum

As of March 18, 2026, 10:13, the constituent stocks of the CSI Pharmaceutical and Medical Device Innovation Index (931484) showed mixed gains and losses,3SBioUp 6.11%,HaiscoIncrease by 1.06%,Nanwei MedicalIncrease by 0.35%;AimekLeading the decline. The latest quote for the Medical Innovation ETF (516820) is 0.36 yuan.

In terms of liquidity, the medical innovation ETF had a turnover rate of 0.58% during the trading session, with a trading volume of 10.6295 million yuan. Over a longer period, as of March 17, the medical innovation ETF averaged a daily trading volume of 51.0169 million yuan over the past year.

In terms of news, on March 17, the website of the National Medical Products Administration released the "Announcement on the Issuance of 26 Medical Device Industry Standards Including <Metal Bone Plates for Bone Joining Implants>." In addition, the National Medical Products Administration recently approved the innovative product registration application for the implantable brain-computer interface hand motor function compensation system from Neuracle Technology (Shanghai) Co., Ltd., marking the world's first market launch of a brain-computer interface medical device. This signifies that the world’s first invasive brain-computer interface medical device has entered the clinical application stage.

Open Source Securities pointed out that brain-computer interface, as a future industry identified in the "15th Five-Year Plan" outline, has received resource prioritization from the National Medical Products Administration (NMPA) during the product evaluation and approval process. Following the principles of "early involvement, tailored strategies for each enterprise, full-process guidance, and synchronized research and review," the NMPA provides pre-assessment services for innovative products, effectively expediting their market entry and significantly enhancing the international competitiveness of China’s high-end medical devices. The "Action Plan for Future Industry Development of Brain-Computer Interfaces (2025–2030)" issued by Shanghai explicitly aims to facilitate the completion of clinical trials for more than five invasive and semi-invasive products by 2027. With Neuracle being the first to break through and go public, we believe that companies such as Step Medical, Xinwei Medical, and Brain Technology also have the potential to accelerate type inspection and clinical trial processes, strengthening the synergistic effects within the brain-computer interface industrial cluster.

The Medical Innovation ETF closely tracks the CSI Pharmaceutical and Medical Device Innovation Index. The CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed company securities with better profitability, certain growth potential, and R&D innovation capabilities from the pharmaceutical and healthcare industry's listed companies as index samples to reflect the overall performance of listed company securities in the pharmaceutical and medical device sectors that combine profitability and growth.

Data shows that as of February 27, 2026, the top ten weighted stocks of the CSI Pharmaceutical and Medical Device Innovation Index (931484) are respectivelyWuXi AppTec、Mindray Medical、Hengrui Medicine、Aier Eye Hospital、Pien Tze Huang、Xinhua、Huadong Medicine、Pharmaron、Ailis、Dong'e EjiaoThe top ten weighted stocks account for 63.75% in total.

Risk Warning: Funds involve risks, and investments should be made with caution. The fund manager commits to managing and utilizing the fund assets in accordance with the principles of honesty, credibility, diligence, and responsibility, but does not guarantee that this fund will definitely make a profit, nor does it guarantee the minimum return. The fund manager reminds investors of the "buyer beware" principle in fund investment. After making an investment decision, the investment risks arising from changes in the fund's operational status and net asset value are borne by the investors themselves. The past performance and net asset value fluctuations of the fund do not predict its future performance. The performance of other funds managed by the fund manager does not constitute a guarantee for the performance of this fund. Investors purchasing the fund may share in the returns generated by the fund investment according to their held shares, but they may also bear the losses brought about by the fund investment. Investors should carefully read legal documents such as the 'Fund Contract' and 'Prospectus' to fully understand the risk-return characteristics and product features of this fund. They should judge whether the fund aligns with their risk tolerance based on their own investment objectives, investment duration, investment experience, and asset conditions. They should rationally assess the market and cautiously make investment decisions. Relevant information in this material comes from publicly available sources deemed reliable by the fund manager. Related viewpoints, evaluations, and predictions only reflect current judgments and may change subsequently. Any market views contained in this material are based on corresponding assumptions, and any assumptions may change at any time. The fund manager does not promise or guarantee that any predictive market views will necessarily be realized. Individual stocks mentioned in the material do not constitute investment recommendations or advice. The secondary market price fluctuation of ETF funds does not represent the actual rate of return; investors should be aware of the risks associated with intraday price volatility.